These two trials tested a low 40 mg daily dose of doxycycline in people with rosacea. The low dose meaningfully reduced inflammatory bumps compared with a dummy pill. Because the dose is too low to act as a full antibiotic, side effects were close to those of placebo. This work supported FDA approval of the 40 mg rosacea formulation (Oracea).